Common questions about Srivasso (FAQ)
Q: Is Srivasso considered a 'rescue' inhaler, or is it for maintenance treatment?
A: Official information states that Srivasso is exclusively for long-term, continuous daily maintenance treatment. It is explicitly not indicated for the immediate relief of sudden, acute breathing problems or episodes of bronchospasm. A separate short-acting inhaler is typically used for rescue when needed, as Srivasso does not fill this role.
Q: What specific conditions or diseases is Srivasso primarily used to treat?
A: Srivasso is approved for the long-term, once-daily maintenance treatment of bronchospasm associated with Chronic Obstructive Pulmonary Disease (COPD), and for reducing COPD flare-ups. It is also approved for the maintenance treatment of asthma.
Q: How quickly should I expect to feel the full breathing benefits of Srivasso after starting it?
A: Srivasso is a long-term maintenance medicine designed to provide a sustained effect over 24 hours. While the medicine is absorbed quickly after inhalation, the full benefit in managing chronic breathing symptoms may develop gradually over the course of days or weeks with continuous daily use.
Q: Does Srivasso treat COPD, asthma, or both, and are the uses different?
A: Srivasso is approved for the maintenance treatment of both COPD and asthma. The uses are different in that a higher dose is typically approved for COPD maintenance compared to the dose approved for asthma maintenance.
Q: What is the difference between Srivasso and a short-acting bronchodilator like albuterol?
A: Srivasso is a long-term maintenance bronchodilator intended for daily, continuous use to keep airways open. In contrast, short-acting bronchodilators (like albuterol) are rescue medicines used only for sudden and immediate relief of acute breathing problems.
Q: What happens if someone accidentally swallows the Srivasso capsule instead of inhaling the powder?
A: The Srivasso capsule must not be swallowed, as the intended therapeutic effects on the lungs will not be fully achieved. Regulatory information suggests that acute intoxication from swallowing the medicine is unlikely because the compound is generally poorly absorbed when ingested orally.
Q: What are the potential effects of suddenly stopping Srivasso after using it regularly?
A: Srivasso works by providing sustained bronchodilation for a full 24 hours. Suddenly stopping the daily medicine would remove this continuous maintenance effect, which could potentially lead to a worsening of chronic breathing symptoms over time.
Q: Does Srivasso help to prevent exacerbations or 'flare-ups' of COPD?
A: Yes, Srivasso is indicated to reduce the risk of COPD exacerbations (flare-ups). It is important to know that a sudden worsening of breathing, called paradoxical bronchospasm, may occur immediately after inhalation and requires treatment with a rescue inhaler.
Q: Can Srivasso cause problems with vision, such as blurred vision or red eyes?
A: Official information states that blurred vision is a reported side effect of Srivasso. Patients are generally advised to be alert for signs of a condition called acute narrow-angle glaucoma, which can include symptoms like eye pain, blurred vision, or seeing halos, often along with red eyes.
Q: Why do some people experience hoarseness or a fungal infection in the mouth after using Srivasso?
A: Hoarseness (dysphonia) is a known side effect reported with Srivasso. While hoarseness is a reported side effect, the official safety reports do not explicitly list fungal infection of the mouth (thrush). However, some inhaled medicines may lead to inflammation of the mouth (stomatitis) or tongue (glossitis).
Q: Are there any food, drink, or supplements that should be avoided when taking Srivasso?
A: Regulatory documents indicate there are no specific interactions documented with food, alcohol, or herbal supplements due to the medicine's inhalation route. The main restriction is to avoid taking Srivasso at the same time as other medications that have anticholinergic properties.
Q: Does Srivasso interact with common over-the-counter cold and flu medications?
A: The most significant drug interaction risk is with other medications that have anticholinergic activity. Patients should be aware that the ingredients of OTC cold or flu medicines may contain anticholinergic components, and co-administration with Srivasso should be avoided in such cases.
Q: How does Srivasso impact exercise tolerance and overall quality of life for COPD patients?
A: Clinical studies for Srivasso measured outcomes such as health-related quality of life and changes in the feeling of shortness of breath (dyspnea). These measurements reflect improvements in how patients feel and their ability to perform daily activities, which can include exercise.
Q: Are there any reports of Srivasso causing a cough that doesn't produce mucus?
A: Cough is listed as a common side effect reported in clinical trials. The regulatory label, however, does not specify the exact nature of the cough—whether it is typically dry or productive (producing mucus).
Q: Is it possible for Srivasso to cause symptoms like dizziness or headache?
A: Yes, regulatory documents list both dizziness and headache as common adverse reactions that were reported by patients during clinical trials.
Q: Why is a dry mouth side effect associated with the type of drug Srivasso is?
A: Srivasso is an anticholinergic drug, meaning it blocks the action of a natural body chemical called acetylcholine. Because this action also affects the glands that produce saliva, it can suppress their secretions, which is the underlying cause of the common side effect of dry mouth.
Q: What research supports the use of Srivasso in asthma?
A: Research supports Srivasso’s role as an add-on controller therapy for asthma patients whose symptoms are not fully managed by standard treatments. Studies tracked outcomes like lung function and the rate of severe asthma flare-ups in both adolescents and children aged 6 and older.
Q: How was the effectiveness of Srivasso measured in clinical trials?
A: The effectiveness of Srivasso was measured primarily through objective assessments of lung function, specifically tracking the forced expiratory volume in one second (known as the FEV1). Studies also monitored clinical outcomes such as the frequency of COPD exacerbations.
Q: Are there any concerns about Srivasso affecting my ability to drive or operate machinery?
A: Since side effects like dizziness and blurred vision may occur, official patient information advises caution when performing activities such as driving a car or operating machinery.
Q: Is it normal to still need a rescue inhaler when taking Srivasso daily?
A: Yes, it is normal and expected. Srivasso is solely for long-term maintenance and is not a rescue medicine. It is generally expected that a short-acting inhaled bronchodilator will still be needed as required for sudden, acute symptoms of shortness of breath.
Q: Why do some people report an initial feeling of a racing heart or agitation after starting Srivasso?
A: A faster heartbeat (tachycardia) and feelings of a racing heart (palpitations) are reported side effects. Insomnia (difficulty sleeping) is also reported and may contribute to a feeling of restlessness or agitation when starting the medicine.
Q: What precautions should be taken if Srivasso powder accidentally gets into the eyes?
A: Care must be taken to avoid allowing the inhalation powder to enter the eyes, as this can cause blurring of vision and pupil dilation. If this happens, or if symptoms like eye pain or red eyes develop, a healthcare professional should be consulted immediately.
Q: Is there a maximum number of years someone can safely use Srivasso?
A: Regulatory information indicates that clinical trials reviewed for the safety and effectiveness of Srivasso included long-term studies that lasted up to four years in adult COPD patients.
Q: What is the relationship between Srivasso use and the risk of developing dental caries (cavities)?
A: A very common side effect of Srivasso is dry mouth. While the medicine's label does not directly address dental caries, having a persistent dry mouth can be a risk factor for oral health issues.
